熱門資訊> 正文

Emergent BioSolutions签署CNJ-016合同修改授予

2025-07-09 05:25

Emergent BioSolutions (NYSE:EBS) announced a modification to its contract to provide its smallpox vaccine, CNJ-016, to the Administration for Strategic Preparedness and Response, part of the U.S. Department of Health and Human Services.
The administration has opted to secure additional doses of this treatment under its existing 10-year contract, which addresses complications arising from smallpox vaccination.

More on Emergent Biosolutions

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
Emergent BioSolutions Inc. 2025 Q1 - Results - Earnings Call Presentation
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress
Emergent Biosolutions Q1 2025 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。